Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Monday, January 31, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Completes Acquisition of RxAir Industries

CENTERVILLE, MA � January 31, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has completed an agreement securing the acquisition of RxAir Industries, LLC, ("RxAir") headquartered in Dallas, Texas.
RxAir (www.rxair.com) is a well-known and highly regarded manufacturer of high quality air purification equipment designed for applications within the medical and hospitality marketplace, and also includes products geared for specialized industrial applications, such as emergency preparedness.
The agreement includes a patented, trademarked product line, with national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The Company has been in business for 15 years, and existing sales include an installed base of several thousand units in over 1000 unique facilities nationwide, including over 400 hospitals. The Company's two main products, the RX3000, which is the Company's best seller, provides air purification coverage in spaces up to 2000 sq. ft, while the RX4500, also known as the "Smoke Handler," is the preferred choice of hospitality establishments nationwide. The unit protects spaces of up to 5000 sq. feet, and can be connected to existing ductwork. Both units can remove more than 99.97% of airborne contaminants and pathogens greater than 0.3 micrometers in size and are designed with exterior cabinetry able to match any d�cor. They combine multiple filter configurations, including HEPA, with germicidal UV lamps, making one of the most effective air purification systems in the world today.
"This acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a U.S. manufacturing base to aid our efforts in the pursuit of medical, hotel, casino, government and DoD contract opportunities, including military and government facilities," said Mr. John Lennon, President of UV Flu Technologies. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital and hospitality marketplace. The larger models and coverage that the RxAir units add to our product line open up a whole new marketplace for us. Larger public spaces like school cafeterias, gaming areas, restaurants, gymnasiums, and construction sites are now just some of the many potential new targets for our products. We believe the synergies will be extraordinary and hope to significantly increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for increased traction across the entire segment."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Tuesday, January 25, 2011

Biotech/Pharma Stock News; BioSante (NASDAQ: BPAX) Announces FDA Orphan Drug Designation for its Melanoma Cancer Vaccine

LINCOLNSHIRE, Ill. - January 25, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.
The orphan drug designation for the Melanoma Cancer Vaccine is BioSante's fourth orphan drug designation for BioSante's portfolio of cancer vaccines; the company also has received orphan drug designations for its vaccines to treat pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia.
"We continue to develop our vaccine portfolio in cooperation with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center," said Stephen M. Simes, president and chief executive officer of BioSante. "Clinical trials of our cancer vaccines are being conducted to treat leukemia, breast cancer, and pancreatic cancer, among other cancer types. In addition, we expect to report on pancreatic cancer study results in the near future."
It is estimated that, in the U.S., over 68,000 people were diagnosed with and 8,700 died of melanoma in 2010. While it is more common in Caucasian populations living in sunny climates, it can be found in almost any groups, including those who use tanning salons. Melanoma is the most serious form of skin cancer, however, if it is recognized and treated early, it is nearly 100 percent curable. But if it is not, the cancer can advance and spread to other parts of the body, where it becomes difficult to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Monday, January 24, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Signs First Distributor Exclusive to Personal Esthetics Sector

CENTERVILLE, MA � January 24, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the Company's flagship product, the ViraTech UV-400 indoor air purifier, is now being distributed through the Perfect Touch Beauty Network ("Perfect Touch") targeting the growing need for improved air quality at beauty salons across the country.
The driving force behind Perfect Touch is its industry renowned principal Debi Nemeth, a respected innovator, distributor and trainer headquartered in Colorado, who works with one of the top nail salon supply companies in the country, training and supplying over 200 nail technicians annually in Colorado, and from surrounding states. The nail salon supply company distributes products, trains estheticians and management, plus licenses hundreds of branded locations throughout the Country and around the globe. Ms. Nemeth trains new and current nail salon owners, particularly with respect to new products and technologies, while also providing an esthetics training curriculum for three colleges within Colorado.
"I not only train and distribute nail products, I'm an owner of a salon, which gives me the ability to test all of the products I distribute, as we only use the best," said Ms. Nemeth. "As a salon owner as well as an educator it was impressive to experience such immediate results. When we brought the ViraTech UV-400 into our salon, our clients couldn't believe the difference! They actually noticed there was no smell in the salon whatsoever, other than a fresh, outdoor quality. Our customers really appreciate that we value their health and my staff has not had one sick day since we brought in the device. I recommend it as an essential piece of equipment for any salon owner, as it pays for itself within weeks by bringing in more business, while also reducing absenteeism."
"Salons all over the Country are already starting to experience regulations on hygiene, and air quality inside their businesses," said John Lennon, President of UV Flu Technologies. "Product trainers and distributors alike that have tried our product truly think it is a game changer, as it protects employees, as well as customers, from toxic fumes and noxious odors, while also keeping them healthy from the spread of airborne bacteria. The units are increasing salon business, while dramatically decreasing the number of complaints from neighbors, particularly with respect to operations located within malls. We think Ms. Nemeth will be incredibly helpful in educating salon owners that this is a product that really works."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Thursday, January 20, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Ships ViraTech UV-400 to Hotel and Assisted Living Industry Sectors

CENTERVILLE, MA � January 20, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce one of UV Flu's distributors, INE Global, has placed an order with The Rogerson House, one of Boston's pre-eminent Assisted Living Facilities. As one of 26 facilities serving almost 1500 Boston-area families, the facility caters to people with memory loss, and is one of the few organizations that actually encourage their residents to own pets. The units are going to be used in the dining and common areas of the facility, where odor control alongside the UV-400s' bacteria killing capabilities will offer a significant decrease in compromised air quality and prevalence of odors.
"We are finding that our products' ability to reduce odors, including from pets and cigarettes has become almost as big of a selling point as the UV-400's ability to kill bacteria and other organic contaminants," said John Lennon, President of UV Flu. "We believe strongly that keeping staff, patients, and visitors safe from the spread of airborne bacteria and viruses should be a national concern. Even though we are still at an early stage with respect to increasing awareness of the dangers of poor indoor air quality, we aim to demonstrate the value of our products by getting them into action, especially in particularly illness-prone environments."
In related news, the Company announced a shipment to Boston's Liberty Hotel, one of the city's foremost 5 Star Hotels, featuring 298 guest rooms and suites.
"The Liberty Hotel is a cutting edge, pet friendly property, with a variety of celebrities counted among their frequent guests," said John Lennon, President of UV Flu. "As such, odor control, particularly from pet odors, or cigarette smoke in non-smoking rooms, has become an increasingly critical element in delivering customer satisfaction. The UV-400 breaks down cigarette smoke and other odors, while killing airborne contaminants, making it a must for most hotel properties."
The Company invites all Hospitality Sector Managers, Operations Leaders and Purchasing Agents to contact UV Flu Technologies to discuss the solutions now offered in a growing number of premier properties and to find out how the UV-400 can offer immediate relief from airborne odors and bacteria in chronic problem spaces within almost any commercial property or public facility.
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Wednesday, January 19, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Commences Product Shipments to Indian Medical and Hospitality Market via Distribution Agreement With Ormed Systems

CENTERVILLE, MA � January 19, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that the Company will commence shipments this week to its newest Asian distributor, Ormed Systems ("Ormed") of Mumbai, India, for distribution to the Medical and Hospitality marketplace throughout the subcontinent. Ormed will use the first shipment for demonstration purposes with key opinion leaders in the management and supply of surgery, pathology, and operating rooms. Ormed will also deploy staff at relevant conferences and workshops in order to enhance market penetration of the Hospitality Sector.
"Ormed Systems is the second international distributor that UV Flu has formed relationships with over the last few months," said Jack Lennon, President of UV Flu Technologies. "India, with a population of 1.15 billion people, is the second biggest marketplace after China. The country has unique health problems, much of which is a direct result of compromised air quality particularly in the major population hubs. We think India could become a very strong market for our products as well as for some of the future offerings we will soon be presenting based on our planned acquisitions."
Mr. Lennon further stated, "In addition to India, we will be shipping another order to Europe over the next several days, and we anticipate significant new orders as a result of our dealer presence at a key industry trade show taking place in Paris this week."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Saturday, January 15, 2011

Biotech Stocks ; MicroCap Investor Portfolio's Top Performer of the Week

Biotech Stocks ;  MicroCap Investor Portfolio's Top Performer of the Week 



January 14, 2011 -- The shares of this developer of a new class of cancer therapeutics are up 260% since Josh first recommended them to his subscribers. The stock is off to a strong start in 2011, surging 57% since December 31. The value of this biotech, which has a long-standing partnership with a leading biopharma and a healthy cash hoard, lies in the ability of its drugs to be used in combination therapies and its excellent prospects for attracting licensees.


Josh Levine's MicroCap Investor is a potential millionaire-maker service for investors with long time horizons and who are prepared for the volatile ups and downs of the microcap world.

The strategy for MicroCap Investor is simple: to focus on small, innovative companies representing the best pure plays in the fast-growing waves of change in biotechnology, cleantech, and other advanced and emerging technologies.

This is a great opportunity to put Josh's expertise to work for you in this often over-hyped and misrepresented -- yet dramatically under-researched -- part of the market, where severe market inefficiencies create opportunities for huge profits.



Josh's mission is to make sure the research is done, and done right. And that's just what he has been doing for years in the world of microcaps.

Learn more http://www.levinesmicrocapinvestor.com/subscriptions/order/


or http://www.levinesmicrocapinvestor.com/



More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !

Wednesday, January 12, 2011

Biotech Stocks Directory Updated for 2011; Over 550 Biotech Companies on TSX, OTC, NASDAQ, NYSE and Global Stock Exchanges

POINT ROBERTS, Wash., January 12 , 2011 - www.InvestorIdeas.com, a global investor research portal, specializing in sector research including biotech stocks, updates investors with content and stock directories to research the industry for 2011.

The Biotech Stocks Directory features over 550 publicly listed Biotech, Pharma and Life Sciences Stocks, on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory covers all sub sectors of biotech including nanotech, biodefense and stem cell stocks.
Preview the biotech stocks directory: http://www.investorideas.com/BIS/Stock_List.asp

The biotech stocks directory is available separately in a PDF of part of the Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water, mining, defense, nanotech and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/

Other biotech investor research within Investorideas.com includes the Biotech investor portal within the content hub, http://www.biotechindustrystocks.com/
Showcase biotech companies are featured for additional investor research. 
Current list of stock directories at Investorideas.com for investors:
Renewable Energy Stocks Directory - Global Green and Renewable Energy Stocks Directory in PDF format includes over 1200 stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges . The directory features hyperlinks to stocks symbol(s), company’s URL and company’s description. The directory includes info and links on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure Stocks. For investors following green stocks, this is the most comprehensive global stock directory online.
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory in PDF format lists over 1100 publicly traded mining companies. Mining and metals investors can research gold and mining stocks with the mining stocks directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks, Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges. directory features hyperlinks to stocks symbol(s), company’s URL and company’s description.

Oil and Gas Stocks Directory - Global Oil and Gas Stocks Directory of Publicly traded oil and gas stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The comprehensive directory gives investors a full range and choice of micro cap to large cap stocks in the energy sector. The directory in PDF format, features hyperlinks to over 600 stocks symbol(s), company's URL and company's description.

Coal Stocks Directory - Global Directory of Publicly traded Coal stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, China and other leading global Stock Exchanges . The comprehensive directory gives investors a full range and choice of micro cap to large cap stocks in the coal sector, including clean coal and coking coal stocks. The directory in PDF format, features hyperlinks to coal stocks symbol(s), company's URL and company's description.

Defense Stocks Directory - Global Defense and Homeland Security Stocks Directory features publicly traded defense stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory, in PDF format, includes Homeland Security Stocks, Aerospace and Defense Stocks, Biodefense Stocks, Security Stocks, Energy Security Stocks and Infrastructure Stocks with hyperlinks to stocks symbol(s), company's URL and company's description. For defense stocks followers, this is one of the most comprehensive global stock directories available to investors.
Water Stocks Directory - Global Water Stocks Directory of publicly traded water stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The stock directory features water stocks ranging from desalination companies to bottled water stocks, to infrastructure, water treatment and technology as well as other sub sectors. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description. For investors following water stocks this is one of the most comprehensive directories in the sector available.

Environment Stocks Directory - Global Green Stocks Directory of Publicly traded Environmental Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description.

Fuel Cell Stocks Directory - Global Directory of Publicly traded Fuel Cell Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for review. For green investors looking for opportunities in the fuel cell sector, the comprehensive global directory in PDF format provides a great research tool with hyperlinks to stocks symbol(s), company's URL and company's description.

Biotech Stocks Directory - Global Directory of Publicly Traded Biotech,Pharma and Life Sciences Stocks ,on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges . The directory covers all sub sectors of biotech including nanotech, biodefense and stem cell stocks. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for investors The comprehensive global directory in PDF format provides a great research tool for biotechnology investors with hyperlinks to stocks symbol(s), company's URL and company's description.

Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks included range from LNG, Coal Bed Methane to exploration and producers in the sector. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description.

Nanotechnology Stocks Directory - Investorideas.com global stock directory of publicly traded nanotech stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, Hong Kong and China and other leading Stock Exchanges. Directory includes nanotech- biotech companies, nanotech water and renewable energy companies and more. Directory features company description, stock symbol and hyperlink to recent quote and info, link to website and more.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/

Sign up for the free investor news letter and get stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp

About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector investing content.

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com

Source – Investorideas.com

Monday, January 10, 2011

Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Confirms Female Sexual Dysfunction as an Unmet Medical Need

LINCOLNSHIRE, Ill. - January 10, 2011 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD). The multiple surveys, conducted independently for BioSante by Campbell Alliance Group, Inc., revealed sexual dysfunction to be one of the most common complaints received in these doctors' offices. The physicians described themselves as dissatisfied with the current lack of therapeutic options for HSDD, a loss of libido or sexual desire.
Stephen M. Simes, president and CEO of BioSante, said, "The need for an FDA-approved treatment to cope with this condition is accepted by an astonishing over 90 percent of the doctors surveyed by Campbell. It has been more than a decade since the FDA approved Viagra for the treatment of male sexual dysfunction; it is time to provide women and their healthcare providers with a safe and effective option."
BioSante is developing LibiGel®, a testosterone gel, for treatment of HSDD in menopausal women. LibiGel is currently in three Phase III clinical studies to prove its safety and efficacy.
The doctors surveyed indicated that if their patients are not experiencing relationship problems or some other condition that could suppress their desire for sex, therapeutic options should be considered. However, there are currently no FDA-approved therapeutic treatment options for women with HSDD. A significant number of physicians (over 90 percent) reported that they prescribe off-label testosterone for women to treat FSD, however, these physicians are dissatisfied with the non-FDA approved, off-label alternatives. Nationally, it is estimated that 4.1 million of such off-label prescriptions are filled annually.
The doctors were asked their reactions to an unnamed therapeutic that fit LibiGel's profile. An overwhelming percentage (94%) responded favorably, as long as it is proven to be safe. BioSante is conducting a Phase III multicenter cardiovascular and breast cancer safety study. Based on approximately 2,800 women in the safety study for an average of approximately 11.5 months each, there have been only 14 adjudicated cardiovascular (CV) events, a rate of approximately 0.52 percent, compared to an expected rate of approximately two percent and only eight diagnoses of breast cancer, a rate of approximately 0.30 percent, compared to an expected rate of approximately 0.35 percent, after approximately 2,700 women-years of exposure in the study.
According to Michael Snabes, MD, PhD, BioSante's senior vice president of medical affairs, "If testosterone increased the incidence of cardiovascular events, we would see a higher rate of such events, especially since the study subjects are at the higher end of cardiovascular risk for the intended treatment population. The expected rate of cardiovascular events in the women in the study is approximately two percent. Based on the safety seen to date, we believe that LibiGel will be the first product approved by the FDA to treat HSDD in menopausal women." BioSante anticipates the submission of a new drug application for LibiGel in 2011 and a product launch in 2012.
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD). The two on-going Phase III efficacy trials are double-blind, placebo-controlled trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily, pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p < 0.0001); this increase also was significant versus placebo (p < 0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, future market size, acceptance and potential of LibiGel and other statements identified by words such as "will," "potential," "could," "would," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.

Wednesday, January 5, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Executes Online Sales Agreement for ViraTech UV-400

CENTERVILLE, MA � January 5, 2011 (Investorideas.com Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce the availability of the ViraTech UV-400 air purifier on two new sales websites, and that the Company is in talks to feature the product on a number of other e-commerce providers as early as the end of January. The product is now available for online distribution at www.uv-400.info and www.livingdirect.com.
"Targeted online sales signify a tangible sales ramp-up that we have been working on since the product became available this summer," said Jack Lennon, President of UV Flu Technologies. "This month we anticipate shipping more product than during the entire history of the Company and plan to be featured on multiple websites as well as mounting a presentation showcasing the product during a major industry trade show in Paris. We are also in talks to launch the UV-400 via a major distributor in India, and aim to follow this with introductory offerings in the Middle East. We are working to close our previously announced manufacturing acquisition in the coming weeks and to introduce the resulting new product line to our international and domestic distributors as soon as possible. We will be announcing shipments to several notable hotel properties during the first quarter, and have also identified opportunities to gain traction across a number of vertical market segments early in the New Year. We are working hard on several significant fronts which we hope to close and announce as quickly as commercially practical."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on Investorideas.com (please read disclosure and disclaimers)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/UVFT/

Request info:
http://www.investorideas.com/Resources/Newsletter.asp

Monday, January 3, 2011

Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Closes $18 Million Registered Direct Offering to Fund LibiGel for Female Sexual Dysfunction

LINCOLNSHIRE, Ill. - December 31, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced closing of a previously announced sale of an aggregate of $18 million of securities in a registered direct offering. BioSante received net proceeds of approximately $16.9 million after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 10.6 million shares of its common stock and warrants to purchase up to approximately 5.3 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, was sold for a purchase price of $1.70, a premium to the closing price on the prior full trading day before the securities purchase agreements were signed.
The warrants to purchase additional shares are exercisable immediately at an exercise price of $2.00 per share and will expire on December 29, 2015. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used for general corporate purposes, including BioSante�s LibiGel Phase III clinical study program. LibiGel remains the lead pharmaceutical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, and BioSante believes that LibiGel has the potential to be the first product approved by the FDA for this common and unmet medical need.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ:RODM), acted as the exclusive placement agent for the transaction. Roth Capital Partners, LLC, JMP Securities LLC, Oppenheimer & Co. Inc. and Trout Capital, LLC acted as financial advisors.
All of the securities were offered and sold pursuant to an effective shelf registration statement filed by BioSante with the Securities and Exchange Commission. This announcement is neither an offer to sell nor a solicitation of an offer to buy any shares of common stock or warrants of BioSante. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products and other statements identified by words such as �will,� �potential,� �could,� �can,� �believe,� �intends,� �continue,� �plans,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
BioSante Pharmaceuticals
For Media:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Investors:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Visit the BPAX showcase profile at Investorideas.com
Request News and Info on BPAX
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.